NRG-GI008: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

Brief description of study

You can participate in this study if you are diagnosed with stage 2 or stage 3 colon cancer. The purpose of this study is to compare the time of the recurrence of the tumor after surgery followed by immediate chemotherapy or delayed chemotherapy. This response would be compared by analyzing the level of post-operative and serial circulating tumor DNA (ctDNA) status. Circulating tumor DNA is a DNA, which originates from the cancerous cells and can be detected in the bloodstream. This study also determines the efficacy of FDA-approved anti-cancer drugs; fluoropyrimidine, oxaliplatin and irinotecan, when used in combination or individually. For this study, the patients will be assigned into two groups; one group will receive fluoropyrimidine plus oxaliplatin plus irinotecan, and the other group will receive fluoropyrimidine plus oxaliplatin. The patients will be monitored and taken care of while on these medications during the entire study period.


Clinical Study Identifier: s22-00453
ClinicalTrials.gov Identifier: NCT05174169
Principal Investigator: Michael Shusterman.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.